Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Palladini, Giovanni
EMN22, NCT04131309 / 2018-004333-33: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis	Active, not recruiting	2	40	Europe	Daratumumab, Bortezomib Injection, velcade, Dexamethasone oral tablet	Stichting European Myeloma Network, Janssen Pharmaceutica	Light Chain (AL) Amyloidosis, Stage 3B	01/25	01/25
EMN27, NCT04617925 / 2020-004001-32: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis	Active, not recruiting	2	35	Europe	Belantamab mafodotin	Stichting European Myeloma Network, GlaxoSmithKline	AL Amyloidosis	07/25	07/25
ZN-d5-003, NCT05199337 / 2021-003008-42: Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	Completed	1/2	18	Europe, US, RoW	ZN-d5, Study Drug	K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., K-Group Alpha, Inc	Amyloidosis, AL Amyloidosis	02/24	02/24